As of 2024-12-12, the Relative Valuation of Bristol-Myers Squibb Co (BMY) is 0.44 USD. This relative valuation is based on P/E multiples. With the latest stock price at 56.65 USD, the upside of Bristol-Myers Squibb Co based on Relative Valuation is -99.2%.
The range of the Relative Valuation is (99.34) - 127.68 USD.
| Range | Selected | |
| Trailing P/E multiples | 27.8x - 32.3x | 30.0x |
| Forward P/E multiples | 22.5x - 34.7x | 29.4x |
| Fair Price | (99.34) - 127.68 | 0.44 |
| Upside | -275.4% - 125.4% | -99.2% |
| Date | P/E |
| 2024-12-06 | -16.59 |
| 2024-12-05 | -16.44 |
| 2024-12-04 | -16.31 |
| 2024-12-03 | -16.40 |
| 2024-12-02 | -16.75 |
| 2024-11-29 | -16.55 |
| 2024-11-27 | -16.56 |
| 2024-11-26 | -16.41 |
| 2024-11-25 | -16.43 |
| 2024-11-22 | -16.45 |
| 2024-11-21 | -16.27 |
| 2024-11-20 | -16.17 |
| 2024-11-19 | -16.27 |
| 2024-11-18 | -15.87 |
| 2024-11-15 | -15.71 |
| 2024-11-14 | -16.35 |
| 2024-11-13 | -16.32 |
| 2024-11-12 | -16.49 |
| 2024-11-11 | -16.72 |
| 2024-11-08 | -15.13 |
| 2024-11-07 | -15.29 |
| 2024-11-06 | -15.45 |
| 2024-11-05 | -15.63 |
| 2024-11-04 | -15.49 |
| 2024-11-01 | -15.18 |
| 2024-10-31 | -15.58 |
| 2024-10-30 | -14.72 |
| 2024-10-29 | -14.67 |
| 2024-10-28 | -14.71 |
| 2024-10-25 | -14.51 |
| 2024-10-24 | -14.79 |
| 2024-10-23 | -14.83 |
| 2024-10-22 | -14.74 |
| 2024-10-21 | -14.56 |
| 2024-10-18 | -14.87 |
| 2024-10-17 | -14.86 |
| 2024-10-16 | -14.91 |
| 2024-10-15 | -14.74 |
| 2024-10-14 | -14.72 |
| 2024-10-11 | -14.59 |
| 2024-10-10 | -14.64 |
| 2024-10-09 | -14.75 |
| 2024-10-08 | -14.67 |
| 2024-10-07 | -14.93 |
| 2024-10-04 | -15.08 |
| 2024-10-03 | -15.15 |
| 2024-10-02 | -15.02 |
| 2024-10-01 | -14.78 |
| 2024-09-30 | -14.46 |
| 2024-09-27 | -14.23 |